Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures (SARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03565211
Recruitment Status : Completed
First Posted : June 21, 2018
Results First Posted : November 23, 2020
Last Update Posted : November 23, 2020
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals

Brief Summary:
The purpose of the study is to assess the safety of Progesterone Vaginal Ring (PVR) in women undergoing fresh embryo transfer (ART).

Condition or disease Intervention/treatment Phase
Progesterone Supplementation in Women Undergoing ART Drug: Progesterone vaginal ring Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 352 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: Open-label trial
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Non-Comparative Trial of the Clinical Safety of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology (ART) Procedures
Actual Study Start Date : July 26, 2018
Actual Primary Completion Date : July 29, 2019
Actual Study Completion Date : July 29, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Progesterone vaginal ring (PVR)
Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
Drug: Progesterone vaginal ring
A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.




Primary Outcome Measures :
  1. Cumulative Rate of Spontaneous Abortions Occurring on or Before 12 Weeks Post-oocyte Retrieval [ Time Frame: On or before 12 weeks post-oocyte retrieval ]

    Frequency of participants with spontaneous abortions on or before 12 weeks post-oocyte retrieval and undergoing fresh embryo transfer was presented.

    Spontaneous abortion was defined as two positive beta-human chorionic gonadotropin (β-hCG) tests occurring at least two days apart on or after 2 weeks post-oocyte retrieval, but followed by observation of any empty intrauterine gestational sac (blighted ovum), intrauterine gestation without a fetal heart beat, or absence of viable fetuses, as documented by transvaginal ultrasound (TVUS).



Secondary Outcome Measures :
  1. Cumulative Rate of Spontaneous Abortions Occurring at 6 Weeks Post-oocyte Retrieval [ Time Frame: At 6 weeks post-oocyte retrieval ]
    Frequency of participants with spontaneous abortions at 6 weeks post-oocyte retrieval was presented.

  2. Cumulative Rate of Spontaneous Abortions Occurring at 10 Weeks Post-oocyte Retrieval [ Time Frame: At 10 weeks post-oocyte retrieval ]
    Frequency of participants with spontaneous abortions at 10 weeks post-oocyte retrieval was presented.

  3. Cumulative Rate of Biochemical Abortion Within 6 Weeks Post-oocyte Retrieval [ Time Frame: Within 6 weeks post-oocyte retrieval ]

    Frequency of participants with biochemical abortions within 6 weeks post-oocyte retrieval was presented.

    Biochemical abortion was defined as a positive β-hCG test at 2 weeks and 2 weeks +3-4 days post-oocyte retrieval, but followed by no observed gestational sac on a later TVUS, or followed by a negative β-hCG test.


  4. Cumulative Rate of Biochemical Abortion Within 10 Weeks Post-oocyte Retrieval [ Time Frame: Within 10 weeks post-oocyte retrieval ]
    Frequency of participants with biochemical abortions within 10 weeks post-oocyte retrieval was presented.

  5. Positive β-hCG Rate at 2 Weeks and 2 Weeks +3-4 Days Post Oocyte Retrieval [ Time Frame: At 2 weeks and 2 weeks +3-4 Days post oocyte retrieval ]
    Frequency of participants with positive β-hCG rate at 2 weeks and 2 weeks +3-4 Days was presented. Positive β-hCG was defined as a positive serum β-hCG test at 2 weeks and 2 weeks +3-4 Days post-oocyte retrieval.

  6. Clinical Pregnancy Rate at 6 Weeks [ Time Frame: At 6 weeks post-oocyte retrieval ]
    Frequency of participants with clinical pregnancy at 6 weeks was presented. Clinical pregnancy was defined as a TVUS showing at least 1 intrauterine gestational sac with fetal heart-beat at 6 weeks post-oocyte retrieval.

  7. Clinical Pregnancy Rate at 10 Weeks [ Time Frame: At 10 weeks post-oocyte retrieval ]
    Frequency of participants with clinical pregnancy at 10 weeks was presented.

  8. Rate of Ectopic and Heterotopic Pregnancies Following Oocyte Retrieval [ Time Frame: At 4 weeks +3-4 Days after oocyte retrieval ]
    Frequency of participants with ectopic and heterotopic pregnancies was presented.

  9. Rate of Abnormal Findings in Clinical Laboratory Tests (Clinical Chemistry, Hematology, and Urinalysis) [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Participants with at least one abnormal finding in clinical laboratory tests (i.e. abnormal clinical significant [CS] values: as assessed by investigator) were reported. Clinical chemistry included: glucose, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, creatinine, potassium, sodium, chloride, calcium, estimated glomerular filtration rate, and gamma-glutamyl transferase; hematology included: basophils, eosinophils, hematocrit, hemoglobin, lymphocytes, monocytes, neutrophils, platelets, erythrocytes, and leukocytes; urinalysis included: specific gravity, ketones, pH, protein, blood, and glucose.

  10. Rate of Abnormal Findings in Vital Signs [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Participants with at least one abnormal finding (i.e. abnormal CS values: as assessed by investigator) in vital signs were reported. Vital signs includes: Weight (kg): decrease of >=7% from baseline (BL) or increase of >=7% from BL; Systolic Blood Pressure (SBP): <=90 mmHg and decrease of >=20 mmHg from BL or >=180 mmHg and increase of >= 20 mmHg from BL; Diastolic Blood Pressure (DBP): <= 50 mmHg and decrease of >= 15 mmHg from BL or >=105 mmHg and increase of >=15 mmHg from BL; Heart Rate: <=50 (beats per minute [bpm]) and decrease of >= 15 bpm from BL or >=120 bpm and increase of >=15 from BL; Temperature >= 38.3 degree Celsius.

  11. Frequency, Intensity/Grade, Seriousness, and Relatedness of Adverse Events (AEs) [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    The frequency of participants with total AEs, AEs by categories of intensity (mild, moderate, severe), seriousness and relatedness was presented. An AE is any untoward medical occurrence in a participant participating in a clinical trial. The intensity of an AE was classified using the following 3-point scale: mild=awareness of signs or symptoms, but no disruption of usual activity; moderate=event sufficient to affect usual activity (disturbing); or severe= inability to work or perform usual activities (unacceptable). Seriousness refers to death, hospitalization/ prolongation of existing hospitalization, a life-threatening experience, persistent or significant disability/incapacity, or congenital anomaly. The possibility of whether the IMP caused the AE would be classified as: reasonable possibility, no reasonable possibility. All the reasonable possible causality to the IMP were referred to as adverse drug reactions (ADRs). Relatedness of AEs to IMP was assessed by the investigator.

  12. Frequency and Intensity/Grade of Vaginal Bleeding/Spotting [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Frequency of participants with vaginal bleeding/spotting was presented in total and by categories of intensity/grade (mild, moderate and severe). Vaginal bleeding was recorded in a bleeding log by the participant. The severity of the bleeding was determined using a Pictorial Blood Loss Assessment chart.

  13. Frequency and Intensity/Grade of Vaginal Hemorrhage [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Frequency of participants with vaginal hemorrhage was presented in total and by categories of intensity/grade (mild, moderate and severe). Vaginal hemorrhage was defined as a) blood loss of greater than 500 mL based on the opinion of the Investigator or b) hemoglobin post-treatment lesser than 10 gm/dL or c) blood loss requiring transfusion.

  14. Frequency and Intensity/Grade of Vaginal Pain [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]

    The frequency of participants with vaginal pain was presented in total and by categories of intensity/grade.

    The intensity of vaginal pain was evaluated as symptoms score of pain and dyspareunia (pain with sexual activity) as: Grade 1 (mild) - Pain causing no or minimal inference with usual social & functional activities; Grade 2 (moderate) - Pain causing greater than minimal inference with usual social & functional activities or the need for non-narcotic medication; Grade 3 (severe) - Pain causing inability to perform usual social & functional activities or the need for narcotic medication; Grade 4 (potentially life threatening) - Disabling pain causing inability to perform basic self-care functions OR hospitalization (other than emergency room visit) indicated.

    Dyspareunia (pain with sexual activity): Grade 1 (mild) - Pain causing no or minimal inference with sexual function; Grade 2 (moderate) - Pain causing greater than minimal inference with sexual function.


  15. Frequency and Intensity/Grade of Vaginal Infection [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Frequency of participants with vaginal infection was presented in total and by categories of intensity/grade (mild, moderate and severe).

  16. Frequency and Intensity/Grade of Vaginal Irritation [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    The frequency of participants with vaginal irritation was presented in total and by categories of intensity/grade. The intensity of vaginal irritation evaluated as symptoms score of vaginal itching, vaginal dryness, and vaginal discharge. Vaginal itching: Grade 1 (mild)-itching causing no, mild or moderate inference with usual social & functional activities; Grade 2 (moderate)-itching causing inability to perform usual social & functional activities; may require intervention such as antihistamine or bathing. Vaginal dryness: Grade 1 (mild)-dryness causing no or minimal inference with usual sexual, social & functional activities; Grade 2 (moderate)-dryness causing greater than minimal inference with usual sexual, social & functional activities. Vaginal discharge by participant report: Grade 1 (mild)-mild-moderate increase in amount above participant BL-no sanitary protection required; Grade 2 (moderate)-profuse increase in discharge requiring pad use or other hygienic intervention.

  17. Frequency, Intensity/Grade, Seriousness, and Relatedness of AEs Associated With Vaginal and Cervical Abrasions and Lesions [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Frequency of participants with AEs associated with vaginal and cervical abrasions and lesions, by intensity, seriousness, & relatedness was presented. Intensity was evaluated as symptoms score: Vaginal/cervical lesions:Grade 0 (Normal)- Normal variants including skin tags, moles, scars, etc; Grade 1 (mild) - Blisters, ulcerations, or pustules, no treatment indicated; Grade 2 (moderate)- Blisters, ulcerations, or pustules with treatment indicated; Grade 3 (severe) - Severe epithelial disruption requiring hospitalization; Vaginal/cervical abrasions: Grade 0 (Normal) - None; Grade 1 (mild)- Superficial disruptions and disruptions extending through the mucosa with minimal impact on life; Grade 2 (moderate)- Large disruptions extending through the mucosa or large superficial disruptions, hospitalization not indicated; Grade 3 (severe)- Large disruptions extending through the mucosa or large superficial disruptions, hospitalization indicated. Relatedness to IMP was assessed by investigator.

  18. Frequency, Intensity/Grade, Seriousness, and Relatedness of AEs Associated With Vaginal Adhesions [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]

    The frequency of participants with AEs associated with vaginal adhesion (total), by categories of intensity, seriousness, and relatedness was presented.

    The intensity was evaluated as symptoms score of vaginal adhesion as: Grade 0 (Normal) - None; Grade 1 (mild) - asymptomatic, manual removal of ring possible; Grade 2 (moderate) - Symptomatic (eg: irritation reported by participant), manual removal of ring possible; Grade 3 (severe) - Surgical intervention (eg: adhesiolysis) required to resolve; Grade 4 (potentially life threatening) - urgent intervention indicated. The AEs associated with vaginal adhesion of Grade 4 intensity were considered to be serious. Relatedness to IMP was assessed by investigator.


  19. Frequency and Reason for PVR Discontinuation [ Time Frame: From Day 1 of PVR treatment (day after oocyte retrieval) up to end-of-trial (12 weeks post-oocyte retrieval) ]
    Frequency of participants who prematurely discontinued PVR (i.e. did not fulfill 10 weeks of PVR treatment) was presented by reason.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 34 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Pre-menopausal females aged 18-34 years.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pre-menopausal women aged 18-34 at the time of consent.
  • Documentation of a normal uterine cavity by hysteroscopy, hydrosonogram, or hysterosalpingogram within one year of screening.
  • Normal Pap smear test within 24 months of screening.
  • At least one cycle without reproductive hormone medication prior to screening follicle-stimulating hormone (FSH) and estradiol blood draw.
  • Tubal, idiopathic, male factor, ovulatory dysfunction, or endometriosis-linked infertility.

Exclusion Criteria:

  • Body mass index greater than 38 kg/m^2.
  • FSH greater than 15 IU/L during the early follicular phase (Day 2-4). For those participants with polycystic ovarian syndrome, a Day 2-4 FSH level can be obtained following a progestogen withdrawal or spontaneous menses.
  • Clinically significant gynecologic pathology, such as submucosal fibroids, intramural fibroids >5 cm, communicating hydrosalpinx, uncorrected uterine septum, endometrial cancer or endometrial atypia, scar tissue inside the cavity or poorly developed uterine lining from prior uterine surgery, pelvic tuberculosis, or any other conditions that could adversely affect pregnancy success.
  • Uncontrolled elevation of prolactin or too little thyroid hormone in the blood.
  • History of more than one failed fresh in vitro fertilization cycle. A failed cycle is defined as having started a cycle and not becoming pregnant or pregnancy loss prior to the 20th week of pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03565211


Locations
Layout table for location information
United States, Arizona
Fertility Treatment Center
Tempe, Arizona, United States, 85284
United States, California
HRC Fertility
Encino, California, United States, 91436
United States, Delaware
Reproductive Associates of DE
Newark, Delaware, United States, 19713
United States, Florida
Women's Medical Research Group
Clearwater, Florida, United States, 33759
Center for Reproductive Medicine
Winter Park, Florida, United States, 32789
United States, Idaho
Idaho Center for Reproductive Medicine
Boise, Idaho, United States, 83702
United States, Illinois
InVia Fertility
Hoffman Estates, Illinois, United States, 60169
United States, North Carolina
Carolina Conceptions
Raleigh, North Carolina, United States, 27607
United States, Pennsylvania
Abington Reproductive Medicine
Abington, Pennsylvania, United States, 19046
Main Line Fertility Center
Bryn Mawr, Pennsylvania, United States, 19010
United States, Texas
Center for Assisted Reproduction
Bedford, Texas, United States, 76022
Houston Fertility Institute
Houston, Texas, United States, 77063
Center of Reproductive Medicine
Webster, Texas, United States, 77598
United States, Utah
Utah Fertility Center
Pleasant Grove, Utah, United States, 84062
United States, Virginia
Eastern Virginia Medical School | EVMS Obstetrics & Gynecology
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Global Clinical Compliance Ferring Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Ferring Pharmaceuticals:
Study Protocol  [PDF] August 9, 2019
Statistical Analysis Plan  [PDF] August 9, 2019

Layout table for additonal information
Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03565211    
Other Study ID Numbers: 000293
First Posted: June 21, 2018    Key Record Dates
Results First Posted: November 23, 2020
Last Update Posted: November 23, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ferring Pharmaceuticals:
Progesterone vaginal ring (PVR)
Vaginal progesterone ring
Assisted reproductive technology (ART)
Infertility
Additional relevant MeSH terms:
Layout table for MeSH terms
Progesterone
Progestins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs